Patent search ap:"Robert Kirk Delisle" Page 1

1.

发明授权
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors 有权
Title translation: 取代的N-（1H-吲唑-4-基）咪唑并[1,2-a]吡啶-3-甲酰胺化合物作为III型受体酪氨酸激酶抑制剂

公开(公告)号：US09174981B2

公开(公告)日：2015-11-03

申请号：US13994048

申请日：2011-12-13

Applicant: Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao

Inventor： Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao

IPC: C07D471/04

CPC classification number: C07D471/04 , A61K31/496 , A61K45/06

Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Abstract translation: 式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和R 6具有说明书中给出的含义，是cFMS的抑制剂，可用于治疗纤维化，骨相关疾病，癌症，自身免疫性疾病，炎性疾病，心血管疾病，哺乳动物的疼痛和灼伤。

2.

发明授权
Triazolopyridine compounds as PIM kinase inhibitors 有权
Title translation: 三唑并吡啶化合物作为PIM激酶抑制剂

公开(公告)号：US08557809B2

公开(公告)日：2013-10-15

申请号：US13059881

申请日：2009-08-18

Applicant: Shelley Allen , Robert Kirk DeLisle , Julie Marie Greschuk , Erik James Hicken , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , John E. Robinson , Qian Zhao

Inventor： Shelley Allen , Robert Kirk DeLisle , Julie Marie Greschuk , Erik James Hicken , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , John E. Robinson , Qian Zhao

IPC: A61K31/5377 , A61K31/496 , A61K31/4709 , C07D471/04 , A61P35/02 , A61P29/00

CPC classification number: C07D471/04

Abstract: Compounds of Formula (I): I in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.

Abstract translation: 式（I）的化合物：其中B，R1，R1a，R2，R3，R4，R5，R6，R7，R10和R11具有本说明书中给出的含义的I是可用于治疗疾病介导的受体酪氨酸抑制剂通过PIM-1和/或PIM-2和/或PIM-3激酶。

3.

发明授权
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors 有权
Title translation: 取代的N-（1H-吲唑-4-基）咪唑并[1,2-a]吡啶-3-甲酰胺化合物，为cFMS抑制剂

公开(公告)号：US08841455B2

公开(公告)日：2014-09-23

申请号：US13517938

申请日：2010-12-20

Applicant: Mark Laurence Boys , Michael F. Bradley , Robert Kirk DeLisle , D. David Hennings , April L. Kennedy , Fredrik P. Marmsater , Matthew David Medina , Mark C. Munson , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao

Inventor： Mark Laurence Boys , Michael F. Bradley , Robert Kirk DeLisle , D. David Hennings , April L. Kennedy , Fredrik P. Marmsater , Matthew David Medina , Mark C. Munson , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao

IPC: C07D491/02 , C07D231/56

CPC classification number: C07D471/04 , C07D519/00

Abstract: Compounds of Formula (I): and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4 and R5 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases and pain.

Abstract translation: 其中R1，R2，R3，R4和R5具有本说明书中给出的含义的式（I）化合物及其药学上可接受的盐是cFMS的抑制剂，可用于治疗骨相关疾病，癌症，自身免疫疾病，炎性疾病，心血管疾病和疼痛。

4.

发明授权
Mitotic kinesin inhibitors and methods of use thereof 有权

公开(公告)号：US08580828B2

公开(公告)日：2013-11-12

申请号：US13586355

申请日：2012-08-15

Applicant: Jeremy Hans , Eli M. Wallace , Qian Zhao , Shelley Allen , Ellen Laird , Joseph P. Lyssikatos , John E. Robinson , Christopher P. Corrette , Robert Kirk DeLisle , Walter C. Voegtil

Inventor： Jeremy Hans , Eli M. Wallace , Qian Zhao , Shelley Allen , Ellen Laird , Joseph P. Lyssikatos , John E. Robinson , Christopher P. Corrette , Robert Kirk DeLisle , Walter C. Voegtil

IPC: A61K31/41 , C07D417/04

CPC classification number: C07D513/04 , C07D285/12 , C07D417/04 , C07D417/14 , C07D419/04 , C07D471/04 , C07D487/04 , C07D495/04 , C07D497/04 , C07F9/65395

Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.

5.

发明授权
Triazolopyridine compounds as PIM kinase inhibitors 有权
Title translation: 三唑并吡啶化合物作为PIM激酶抑制剂

公开(公告)号：US08575145B2

公开(公告)日：2013-11-05

申请号：US13059902

申请日：2009-08-18

Applicant: Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Greschuk , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao

Inventor： Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Greschuk , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao

IPC: A61K31/55 , A61K31/437 , A61K31/513 , A61K31/5377 , C07D471/04 , A61P35/00 , A61P25/00 , A61P29/00

CPC classification number: C07D471/04

Abstract: Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.

Abstract translation: 其中A，B，R1，R1a，R2，R3，R4，R5，R6和R7具有本说明书中给出的含义的式（I）化合物是可用于治疗免疫细胞相关的受体酪氨酸抑制剂疾病和病症，例如炎性和自身免疫性疾病。

6.

发明申请
6-SUBSTITUTED PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES 有权
Title translation: 6-取代的苯氧基羧酸衍生物

公开(公告)号：US20110105463A1

公开(公告)日：2011-05-05

申请号：US13001201

申请日：2009-06-24

Applicant: Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff

Inventor： Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff

IPC: A61K31/397 , C07D311/02 , A61K31/352 , C07D405/12 , A61K31/4025 , C07D403/12 , A61K31/453 , A61K31/506 , A61K31/4725 , A61P37/00

CPC classification number: C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12

Abstract: Compounds of Formula (I): in which A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 have the meanings given in the specification, are DP2 receptor modulators useful in the treatment of immunologic diseases.

Abstract translation: 式（I）化合物：其中A1，A2，W，L，G，R7a，R7b，R8，R9和R10具有本说明书中给出的含义，是可用于治疗免疫疾病的DP2受体调节剂。

7.

发明授权
Triazolopyridine compounds as PIM kinase inhibitors 有权
Title translation: 三唑并吡啶化合物作为PIM激酶抑制剂

公开(公告)号：US08889704B2

公开(公告)日：2014-11-18

申请号：US14001657

申请日：2012-02-24

Applicant: James F. Blake , Robert Kirk Delisle , Lisa A. De Meese , James M. Graham , Yvan Le Huerou , Michael Lyon , John E. Robinson , Eli M. Wallace , Bin Wang , Rui Xu

Inventor： James F. Blake , Robert Kirk Delisle , Lisa A. De Meese , James M. Graham , Yvan Le Huerou , Michael Lyon , John E. Robinson , Eli M. Wallace , Bin Wang , Rui Xu

IPC: C07D471/04 , C07D487/04 , C07D487/10 , C07D491/048 , C07D401/06 , C07D519/00

CPC classification number: C07D471/04 , C07D401/06 , C07D487/04 , C07D487/10 , C07D491/048 , C07D519/00

Abstract: Compounds of Formula I: in which R1, R2, R3, R4 and R10 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.

Abstract translation: R 1，R 2，R 3，R 4和R 10具有本说明书中给出的含义的式I化合物是可用于治疗由PIM-1和/或PIM-2和/或PIM-2介导的疾病的受体酪氨酸抑制剂， 3激酶。

8.

发明申请
7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES 有权
Title translation: 7-苯氧羰基羧酸衍生物

公开(公告)号：US20120101103A1

公开(公告)日：2012-04-26

申请号：US13141675

申请日：2009-12-18

Applicant: Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess

Inventor： Adam Cook , Kevin W. Hunt , Robert Kirk Delisle , Todd Romoff , Christopher T. Clark , Ganghyeok Kim , Christopher P. Corrette , George A. Doherty , Laurence E. Burgess

IPC: A61K31/498 , A61K31/497 , A61K31/506 , A61K31/4709 , A61K31/453 , A61K31/444 , A61K31/4433 , A61K31/433 , A61K31/427 , A61K31/428 , A61K31/423 , A61K31/4155 , A61K31/4025 , C07D405/14 , C07D405/12 , C07D417/12 , A61K31/501

CPC classification number: C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12

Abstract: Compounds of Formula I: (I) in which A, A1, R1, R7a, R7b, R8 and R10 have the meanings given in the specification, are DP2 receptor inhibitors useful in the treatment of useful in the treatment and prevention of immunologic diseases, allergic diseases such as asthma, allergic rhinitis and atopic dermatitis, and other inflammatory diseases mediated by prostaglandin D2 (PGD2). The compounds of Formula I may also be useful in treating diseases or medical conditions involving the Th2 T cell via production of IL-4, IL-5 and/or IL-13.

Abstract translation: 其中A，A1，R1，R7a，R7b，R8和R10具有本说明书中给出的含义的式I化合物：（I）是可用于治疗和预防免疫疾病的DP2受体抑制剂，过敏性疾病如哮喘，过敏性鼻炎和特应性皮炎，以及由前列腺素D2（PGD2）介导的其他炎性疾病。式I化合物还可用于通过产生IL-4，IL-5和/或IL-13来治疗涉及Th2T细胞的疾病或医学病症。